Group thinking can be dangerous to your portfolio, Jim Cramer told his Mad Money viewers Wednesday. Just 24 hours ago, the bears were out in force proclaiming that the Trump rally was over and investors needed to take their profits and run. Today however, the market proved otherwise.
Hardly anyone counted on seeing a kinder, gentler Donald Trump when he addressed Congress last night, Cramer said. That has led many to now believe that Trump's campaign promises may actually come true.
More importantly, Cramer said, the market rallied because there are simply too many good things happening around the globe that don't involve Washington.
Even in retail, where the bears latched onto the collapse of Target (TGT - Get Report) , Cramer countered with the terrific numbers from Lowes (LOW - Get Report) . He said it's not uncommon for market-leading sectors to pause, consolidate, and then resume their climb -- which is what we're now seeing in several groups.
Cramer also reminded viewers that in today's 24-hour news cycle, it's too risky to be bullish, but being bearish is always seen as prudent.
When bears run rampant, and few investors have the courage to be bullish -- that's how explosive moves to the upside are born.
Meanwhile, on Real Money, Cramer explains all the factors behind this lively and long-lived bull. Check out his strategies with a free trial subscription to Real Money.
Off The Charts
In the "Off The Charts" segment, Cramer checked in with colleague Bob Lang about the charts of the big pharma stocks, which Cramer believes have been rallying in response to bond yields and not the recent executive meetings with Trump. But the more important question remains, can the rally continue?
Lang first looked at a weekly chart of Pfizer (PFE - Get Report) , noting a bullish "W" pattern with higher highs and higher lows. He also called out the bullish MACD momentum indicator and Chaikin money flow. The last time Pfizer's Chaikin crossed into bullish territory, the stock rallied 20%.
Finally, Lang looked at Action Alerts PLUS holding, Allergan (AGN - Get Report) . After the stock's lackluster performance in 2016, shares have been on fire since December and Lang liked the higher highs and higher lows and this stock's Relative Strength Indicator.
In all, Lang liked Pfizer's chart the best, while Cramer stuck with Allergan for the company's fundamentals, which include a strong product pipeline.
Building on Profits
With Trump talking about spending $1 trillion on infrastructure, is it time to start investing in infrastructure stocks? Cramer featured Martin Marietta Materials (MLM - Get Report) earlier this week, but tonight turned his sights to EMCOR Group (EME - Get Report) and MasTec (MTZ - Get Report) .
While Cramer is skeptical that a huge infrastructure bill will actually make it through Congress, he said both EMCOR and MasTec are safe investments as they benefit from other industries Trump is supporting: oil and gas.
Shares of MasTec are up 40% since the election and the company last posted a 16-cents-a-share earnings beat and forecast a record 2017 based largely on strength in its communications business.
EMCOR is a little tougher, as shares initially rallied after the election, then plummeted after the company reported an 11-cents-a-share earnings miss with conservative guidance. Cramer felt that EMCOR's problems are mostly behind them and said the company is setting up an under-promise and over-deliver situation for next quarter.
Executive Decision: Veeva Systems
For his "Executive Decision" segment, Cramer spoke with Peter Gassner, founder and CEO of Veeva Systems (VEEV - Get Report) , the life sciences cloud software provider that just reported a five-cents-a-share earnings beat -- news that sent shares up 2.7% on the day.
Gassner said that Veeva's Vault product began as a $15 million product and now has a run rate near $220 million. He said it's a unique platform that allows companies to manage content, like documents and files, and also data.
Unlike many cloud software providers, Veeva is able to deliver both high growth and strong profits. The life sciences industry is doing amazing things, Gassner said, and is always looking to streamline its operations.
Gassner explained that the regulatory process for new drugs is very complex and every company is retrofitting its systems to remain in compliance and serve patients better.
The Lightning Round
In his "No-Huddle Offense" segment, Cramer told investors to make sure they consider all of the evidence before convicting a stock and perhaps, also give it the benefit of the doubt.
Sure, there are many investors that are skeptical of Snap, which is set to have its IPO tomorrow. But in the short term, the stock could be a real winner.
Then there's Salesforce.com (CRM - Get Report) , one of the fastest companies to ever reach $10 billion in revenue. Yesterday, the company reported another strong quarter, but shares initially sold off from $83 to $78 on a single metric that was viewed as a disappointment.
Cramer said this stock's long-term performance should outweigh any short-term constraints, especially from a single line item on its earnings.
Cramer and the AAP team are plugging into a tech name. Find out what they're telling their investment club members about Western Digital (WDC - Get Report) with a free trial subscription to Action Alerts PLUS.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.